A MAUDE Database Analysis on the New Generation of Active Bone Conduction Hearing Implants

Overview

Journal Laryngoscope Investig Otolaryngol

Publisher Wiley

Specialty Otorhinolaryngology

Date 2024 Sep 30

PMID 39346784

Authors

Alexander Lein

Wolf-Dieter Baumgartner

Lukas D Landegger

Dominik Riss

Thomas Thurner

David T Liu

Andro Kosec

Erich Vyskocil

Faris F Brkic

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze medical device reports (MDR) submitted to the Food and Drug Administration's (FDA) Manufacturer and User Device Facility Experience (MAUDE) database to identify adverse events (AEs) in patients implanted with novel active bone conduction hearing implants (BCIs).

Methods: We conducted a search of the FDA MAUDE database on the newest generation of BCIs. Data were collected concerning device malfunctions, patient injuries, factors triggering these incidents, and the subsequent actions taken.

Results: In total, 93 (16.7%) device malfunctions and 465 (83.3%) patient injuries with 358 subsequent interventions were identified, resulting in 558 AEs. Although the absolute AE number per device cannot be identified, the following trends were detected: Among the 494 AEs associated with OSI200, 55 (11.1%) reported device malfunctions and 454 (88.9%) cited patient injuries. Out of the 64 AEs linked to BCI602, 28 (59.4%) were associated with malfunctions, whereas 26 (40.6%) involved patient injuries. The most frequently reported particular AEs for the OSI200 were infection ( = 171, 34.6%), extrusion of the device ( = 107, 21.7%), and pain ( = 51, 10.3%). Conversely, no device output ( = 20, 31.3%) and loss of osseointegration ( = 7, 10.9%) were the most reported AEs for the BCI602. Various AEs led to 214 explanations and 77 revision surgeries. Sixty-seven AEs reported conservative treatment.

Conclusion: The current study provides an overview of the most commonly reported complications with new active BCIs. Although providing an overview, given the limitations of the FDA MAUDE database, our results have to be interpreted with caution.

Level Of Evidence: 4.

References

Magele A, Schoerg P, Stanek B, Gradl B, Sprinzl G . Active transcutaneous bone conduction hearing implants: Systematic review and meta-analysis. PLoS One. 2019; 14(9):e0221484. PMC: 6746395. DOI: 10.1371/journal.pone.0221484. View

Patel P, Jayawardena A, Walden R, Penn E, Francis D . Evidence-Based Use of Perioperative Antibiotics in Otolaryngology. Otolaryngol Head Neck Surg. 2018; 158(5):783-800. DOI: 10.1177/0194599817753610. View

Utrilla C, Gavilan J, Garcia-Raya P, Calvino M, Lassaletta L . MRI after Bonebridge implantation: a comparison of two implant generations. Eur Arch Otorhinolaryngol. 2020; 278(9):3203-3209. DOI: 10.1007/s00405-020-06380-2. View

Chew D, Proctor V, Ray J . New Osia® OSI200 active transcutaneous bone-anchored hearing device: how I do it. Eur Arch Otorhinolaryngol. 2022; 280(2):935-939. PMC: 9761039. DOI: 10.1007/s00405-022-07786-w. View

Bestourous D, Davidson L, Reilly B . A Review of Reported Adverse Events in MRI-Safe and MRI-Conditional Cochlear Implants. Otol Neurotol. 2021; 43(1):42-47. DOI: 10.1097/MAO.0000000000003339. View

Sprinzl G, Lenarz T, Ernst A, Hagen R, Wolf-Magele A, Mojallal H . First European multicenter results with a new transcutaneous bone conduction hearing implant system: short-term safety and efficacy. Otol Neurotol. 2013; 34(6):1076-83. DOI: 10.1097/MAO.0b013e31828bb541. View

Nassiri A, Messina S, Benson J, Lane J, McGee K, Trzasko J . Magnetic Resonance Imaging Artifact Associated With Transcutaneous Bone Conduction Implants: Cholesteatoma and Vestibular Schwannoma Surveillance. Otolaryngol Head Neck Surg. 2023; 170(1):187-194. DOI: 10.1002/ohn.474. View

Abdalla I, Choi J, Struyk G, Adams M, Huang T . Magnetic Resonancy Imaging Safety in Active Osseointegrated (Osia®) and Cochlear Implants: New Technology Creating Confusion. Laryngoscope. 2023; 134(1):393-396. DOI: 10.1002/lary.30808. View

Goldstein M, Bourn S, Jacob A . Early Osia® 2 bone conduction hearing implant experience: Nationwide controlled-market release data and single-center outcomes. Am J Otolaryngol. 2020; 42(1):102818. DOI: 10.1016/j.amjoto.2020.102818. View

10.

Cywka K, Skarzynski P, Krol B, Hatzopoulos S, Skarzynski H . Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes. Eur Arch Otorhinolaryngol. 2022; 279(7):3525-3534. PMC: 9130189. DOI: 10.1007/s00405-022-07265-2. View

11.

Cywka K, Skarzynski H, Krol B, Skarzynski P . The Bonebridge BCI 602 Active Transcutaneous Bone Conduction Implant in Children: Objective and Subjective Benefits. J Clin Med. 2021; 10(24). PMC: 8707547. DOI: 10.3390/jcm10245916. View

12.

Brkic F, Riss D, Arnoldner C, Liepins R, Gstottner W, Baumgartner W . Safety and Efficacy of Implantation of the Bonebridge Active Transcutaneous Bone-Conduction Device Using Implant Lifts. J Am Acad Audiol. 2021; 32(5):290-294. DOI: 10.1055/s-0041-1723038. View

13.

Tong J, Pasick L, Benito D, Monfared A, Sataloff R . Adverse Events Associated With Ossicular Prostheses: Utility of a Federal Database. Otol Neurotol. 2021; 43(2):e229-e234. DOI: 10.1097/MAO.0000000000003408. View

14.

Gagliardi A, Ducey A, Lehoux P, Turgeon T, Ross S, Trbovich P . Factors influencing the reporting of adverse medical device events: qualitative interviews with physicians about higher risk implantable devices. BMJ Qual Saf. 2017; 27(3):190-198. PMC: 5867432. DOI: 10.1136/bmjqs-2017-006481. View

15.

Rahne T, Plontke S . Systematic and audiological indication criteria for bone conduction devices and active middle ear implants. Hear Res. 2022; 421:108424. DOI: 10.1016/j.heares.2021.108424. View

16.

Lui J, Dahm V, Arnoldner C, Lam P, Le T, Chen J . How standardised are antibiotic regimens in otologic surgery?. J Otolaryngol Head Neck Surg. 2023; 52(1):73. PMC: 10634121. DOI: 10.1186/s40463-023-00669-y. View

17.

Davies C, Nieri C, Sheyn A, Rangarajan S, Yawn R . The Use and Utility of Food and Drug Administration Adverse Event Data from the Manufacturer and User Facility Device Experience Database in Otology: A Systematic Review. Otol Neurotol. 2023; 44(6):534-541. DOI: 10.1097/MAO.0000000000003899. View

18.

Lein A, Baumgartner W, Riss D, Gstottner W, Landegger L, Liu D . Early Results With the New Active Bone-Conduction Hearing Implant: A Systematic Review and Meta-Analysis. Otolaryngol Head Neck Surg. 2024; 170(6):1630-1647. DOI: 10.1002/ohn.728. View

19.

Kim H, Park M, Park S, Cho H, Choi J, Lee C . Efficacy of the Bonebridge BCI602 for Adult Patients with Single-sided Deafness: A Prospective Multicenter Study. Otolaryngol Head Neck Surg. 2023; 170(2):490-504. DOI: 10.1002/ohn.520. View

20.

Cowan R, Lewis A, Hallberg C, Tong M, Birman C, Ng I . Clinical performance, safety, and patient-reported outcomes of an active osseointegrated bone-conduction hearing implant system at 24-month follow-up. Eur Arch Otorhinolaryngol. 2023; 281(2):683-691. PMC: 10796683. DOI: 10.1007/s00405-023-08133-3. View